Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amphenol Corporation stock logo
APH
Amphenol
$171.11
+2.4%
$161.16
$104.71
$178.52
$206.04B1.246.67 million shs6.30 million shs
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$64.71
+1.4%
$59.75
$42.52
$68.10
$130.39B0.2212.25 million shs7.29 million shs
ERGO
Entia Biosciences
$0.00
$0.00
$0.00
$0.04
N/A26.28867 shsN/A
10 Best Stocks to Own - Summer 2026 Cover

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amphenol Corporation stock logo
APH
Amphenol
+2.38%+1.86%+13.29%+43.50%+56.69%
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
+1.33%-0.06%+6.59%+11.11%+33.56%
ERGO
Entia Biosciences
0.00%0.00%0.00%-66.67%+100.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amphenol Corporation stock logo
APH
Amphenol
$171.11
+2.4%
$161.16
$104.71
$178.52
$206.04B1.246.67 million shs6.30 million shs
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$64.71
+1.4%
$59.75
$42.52
$68.10
$130.39B0.2212.25 million shs7.29 million shs
ERGO
Entia Biosciences
$0.00
$0.00
$0.00
$0.04
N/A26.28867 shsN/A
10 Best Stocks to Own - Summer 2026 Cover

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amphenol Corporation stock logo
APH
Amphenol
+2.38%+1.86%+13.29%+43.50%+56.69%
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
+1.33%-0.06%+6.59%+11.11%+33.56%
ERGO
Entia Biosciences
0.00%0.00%0.00%-66.67%+100.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amphenol Corporation stock logo
APH
Amphenol
3.00
Buy$191.6712.01% Upside
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
2.52
Moderate Buy$66.062.08% Upside
ERGO
Entia Biosciences
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest APH, VEC, ERGO, and BMY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/5/2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
Initiated CoverageMarket PerformStrong-Buy
8/5/2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
Initiated CoverageHoldBuy
8/5/2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
DowngradeBuyNeutral
8/5/2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
DowngradeBuyHold
8/5/2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
Initiated CoverageBuy$75.00
8/5/2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
UpgradeMarket PerformOutperform
8/5/2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
Initiated CoverageOverweight
8/5/2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
UpgradeHoldBuy$75.00
8/3/2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
Reiterated RatingNeutral$66.00 ➝ $70.00
7/31/2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
Reiterated RatingNeutral$54.00 ➝ $59.00
7/30/2026
Amphenol Corporation stock logo
APH
Amphenol
Reiterated RatingBuy$185.00 ➝ $197.00
(Data available from 8/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amphenol Corporation stock logo
APH
Amphenol
$29.01B7.27$4.35 per share39.38$11.03 per share15.51
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$48.19B2.74$8.24 per share7.85$9.09 per share7.12
ERGO
Entia Biosciences
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amphenol Corporation stock logo
APH
Amphenol
$4.27B$3.9942.8826.901.3317.73%39.87%14.80%10/28/2026 (Estimated)
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$7.05B$4.5414.2510.050.1718.87%66.90%14.74%10/29/2026 (Estimated)
ERGO
Entia Biosciences
N/AN/AN/AN/AN/AN/AN/AN/AN/A

Latest APH, VEC, ERGO, and BMY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/30/2026Q2 2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$1.60$2.04+$0.44$1.62$11.74 billion$12.97 billion
7/29/2026Q2 2026
Amphenol Corporation stock logo
APH
Amphenol
$1.19$1.35+$0.16$1.37$8.26 billion$8.76 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Amphenol Corporation stock logo
APH
Amphenol
$1.000.58%+23.60%25.06%N/A
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$2.523.89%+1.61%55.51%17 Years
ERGO
Entia Biosciences
N/AN/AN/AN/AN/A

Latest APH, VEC, ERGO, and BMY Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
8/5/2026
Amphenol Corporation stock logo
APH
Amphenol
quarterly$0.250.59%9/22/20269/22/202610/14/2026
6/17/2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
quarterly$0.634.34%7/2/20267/2/20268/3/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amphenol Corporation stock logo
APH
Amphenol
1.10
1.89
1.41
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
1.89
1.53
1.38
ERGO
Entia Biosciences
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Amphenol Corporation stock logo
APH
Amphenol
97.01%
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
76.41%
ERGO
Entia Biosciences
N/A

Insider Ownership

CompanyInsider Ownership
Amphenol Corporation stock logo
APH
Amphenol
1.42%
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
0.05%
ERGO
Entia Biosciences
28.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Amphenol Corporation stock logo
APH
Amphenol
170,0001.23 billion1.22 billionOptionable
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
32,5002.04 billion2.04 billionOptionable
ERGO
Entia Biosciences
6N/AN/ANot Optionable

Recent News About These Companies

Careology partners with Entia to offer at home blood monitoring
The Best Ergonomic Keyboards for 2024
Hdfc Ergo
Top HDFC ERGO Health Insurance Plans
Cooler Master Hybrid 1 Ergo Gaming Chair Review
Entia Biosciences, Inc. (ERGO)
Entia Biosciences Inc (ERGO)
Entia Biosciences Dividend Per Share (TTM)
Entia Biosciences EPS Diluted (5 Year Growth)
Entia Biosciences Year to Date Total Returns (Daily)
BGF invests $12m in virtual oncology business Entia

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Amphenol stock logo

Amphenol NYSE:APH

$171.11 +4.00 (+2.39%)
Closing price 08/17/2026 03:58 PM Eastern
Extended Trading
$167.39 -3.72 (-2.17%)
As of 07:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Amphenol Corporation, together with its subsidiaries, primarily designs, manufactures, and markets electrical, electronic, and fiber optic connectors in the United States, China, and internationally. It operates through three segments: Harsh Environment Solutions, Communications Solutions, and Interconnect and Sensor Systems. The company offers connectors and connector systems, including harsh environment data, power, high-speed, fiber optic, and radio frequency interconnect products; busbars and power distribution systems; and other connectors. It also provides value-add products, such as backplane interconnect systems, cable assemblies and harnesses, and cable management products; other products comprising flexible and rigid printed circuit boards, hinges, other mechanical, and production related products. In addition, the company offers consumer device, network infrastructure, and other antennas; coaxial, power, and specialty cables; and sensors and sensor-based products. It sells its products through its sales force, independent representatives, and a network of electronics distributors to original equipment manufacturers, electronic manufacturing services companies, original design manufacturers, and service providers in the automotive, broadband communication, commercial aerospace, industrial, information technology and data communication, military, mobile device, and mobile network markets. Amphenol Corporation was founded in 1932 and is headquartered in Wallingford, Connecticut.

Bristol Myers Squibb stock logo

Bristol Myers Squibb NYSE:BMY

$64.71 +0.88 (+1.38%)
Closing price 08/17/2026 03:58 PM Eastern
Extended Trading
$64.76 +0.05 (+0.07%)
As of 07:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Entia Biosciences OTCMKTS:ERGO

$0.0002 0.00 (0.00%)
As of 08/14/2026

Entia Biosciences, Inc. engages in the development, production, and distribution of dietary supplements, nutraceuticals, and medical foods products in the United States. It is also involved in the discovery, scientific evaluation, and marketing of natural formulations that can be used in medical foods, nutraceuticals, cosmetics, and other products. The company's portfolio of formulations include ErgoD2, a pharmaceutical grade organic compound from whole food that contains the micro-nutrients; L-Ergothioneine, a naturally occurring amino acid and master antioxidant; and vitamin D, an antioxidant. In addition, it is also developing products for the chronic kidney disease and other diseases, as well as providing cosmeceuticals and other beauty products under the GROH brand name. Entia Biosciences, Inc. offers its products directly to consumers through e-commerce channels, such as direct email marketing, social media outlets, and e-commerce sites. The company was formerly known as Total Nutraceutical Solutions, Inc. and changed its name to Entia Biosciences, Inc. in January 2012. Entia Biosciences, Inc. was founded in 2007 and is headquartered in Sherwood, Oregon.